Purpose/Objective: Dose-painting by numbers (DBPN) is gaining interest and has the potential to improve tumor local control with minimal increase of side effects. Because of the voxel-by-voxel nonuniform dose prescription in DPBN, usual margin recipes to account for geometric and random uncertainties do not apply. Robust treatment plans may be achieved by incorporating geometric uncertainties during plan optimization. Although powerful, this method is not available in most treatment planning systems (TPS) and may be time-consuming. Our approach aims at providing a universal solution (i.e. TPS independent), by including systematic and random geometric uncertainties implicitly in the prescription for DPBN. Materials and Methods: We propose here a method that modifies the heterogeneous dose prescription D P to ensure robustness of planned dose D Planned against standard deviations of systematic errors Σ and random errors σ. The prescription is based in this study on FDG-PET images with an escalation from 70 to 86 Gy. The objective was that 95% of all voxels in the GTV PET received at least 95% of their respective prescribed dose even in the presence of geometric errors (Q 0.95 >95%). The prescription D P was modified by a morphological dilation of αΣ and a deconvolution by σ (assuming Gaussian distribution). The GTV PET was also extended by αΣ, to generate a PTV PET volume. For a 90% confidence interval, α=2.5. The planning process was performed on a TomoTherapy system such that 95% of the points within PTV PET received at least 95% of the modified prescription (Q 0.95 >95%) and less than 5% of the points received more than 105% of the modified prescription (quality factors Q 0.95 and Q 1.05 are derived from the cumulative quality volume histograms, the quality factor Q being the ratio in each CT voxel between the planned dose and the prescribed dose). Robustness was evaluated by translating and blurring D Planned and by comparing the resulting dose with the unmodified dose prescription within GTV PET . The methodology was illustrated for two head-and-neck tumors treated by helical TomoTherapy. Results: For both patients, the TomoTherapy system was capable to reproduce modified non-uniform prescriptions with Q 0.95 >95% and Q 1.05 <5%. Coverage was preserved when systematic and random displacements were smaller than αΣ and σ. For larger displacements, coverage was degraded. The figure illustrates two examples for one patient. In figure (a), no correction of the prescription was performed, leading to significant underdosage when geometric errors were simulated (down to 62.8% for Q 0.95 ). In figure (b) target coverage was preserved even in the presence of geometric errors.
Conclusions:
The method generates treatment plans that are robust against geometric uncertainties without the need to handle geometric errors in the optimizer of the TPS. The methodology was illustrated for head-and-neck but is potentially general for all tumor sites.
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Development of an angle dependent robustness quality factor for proton/ion beam in cancer treatment J. 
Dept. of Medical Physics, Aarhus University Hospital, Aarhus N, Denmark
Purpose/Objective: With ion therapy it is possible to deposit dose very precisely, however it is still more sensitive to setup errors, interfractional and intrafractional movements than traditional photon therapy. When physicists create treatment plans, angle selection is solely governed by their intuition and experience. Here, we present a model which within seconds can quantify angle quality from CT images and structure information for use selection of robust beam orientations.
Materials and Methods:
The model creates a 2D grid orthogonal to the beam axis at the isocenter. The outer contour of the PTV is projected on the grid and the water equivalent path length (WEPL) along the particle trajectories are calculated in each pixel of the grid. The robustness quality factor (RQF) is determined as 10 minus the mean sum of squares of the WEPL pixel-to-pixel variations, i.e. the maximum value of 10 represents a perfectly robust plan. A CT scan of a tumour of pituitary gland is used for validation of the model. The robustness quality factor is then mapped for the entire angular space covered by the gantry and couch. Islands of good, intermediate and poor angels can be identified, and 15 angles are selected from these regions. The 15 angles are then used as validation points for the model, in terms of systematic and random errors. The field is optimised so the mean dose is 100% in PTV using the treatment planning system TRiP. The resulting plan is then shifted with systematic offsets along the lateral direction of the beam, and the RQF is determined. All recalculations and data analysis are done by PyTRiP. For evaluating the plan against systematic setup errors we score the V-95% of CTV and evaluate an average setup offset for which the 2% of the CTV get less than 95% of prescribed dose. For random errors a new dose distribution is generated by adding the dose distributions sets with varying offset and weighting them with a Gaussian distribution centered at zero offset. In the summed dose distribution, the V-95% of CTV is calculated and used directly as a quality estimator for the plan. Results: For the random error analysis, the V-95% of CTV depends slightly on RQF. Values close to 10 (i.e. robust plans) turns out to give good coverage, and vice versa. However, angles with intermediate RQF show no clear behavior. For systematic errors there a straightforward dependency on the RQF can be observed. For a PTV with a margin of 4 mm and a robustness quality factor of 5, then the mean offset to underdose 2% of the tumour is in the order of 1 mm or below. For a quality factor of 9, this is in the order of 2.5 mm.
Conclusions:
We have succeeded to create a model which can quantify the quality of a chosen beam angle against positioning offset errors. The quality is represented by the RQF, and its validity was checked against systematic and random errors. We demonstrate that RQF is a good representation of the robustness against positioning errors. However, tests on additional patient cases may still be needed. 
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Purpose/Objective: For patients with metal hip implants AAPM taskgroup 63 recommends avoidance of beams that deliver dose to the target while first (in part) passing through the implant. Especially for patients with bilateral prostheses, this severely limits the search space for beam angle selection, generally resulting in less favorable dose distributions since primarily only anterior and posterior beams can be selected. In this study, we compared this approach with an alternative strategy. Materials and Methods: All plans were generated fully automatically (i.e., no human trial-and-error interactions) using iCycle, our in-house developed algorithm for multicriterial optimization of beam angles and fluence profiles, allowing objective comparisons of planning strategies. For 18 prostate cancer patients (8 with bilateral hip prostheses, 10 with a right-sided unilateral prosthesis), two planning strategies were evaluated: i) full exclusion of beams containing nd ESTRO Forum 2013 beamlets that would deliver dose to the target after passing a prosthesis (IMRT remove , recommended by AAPM), and ii) exclusion of only those beamlets including a 5 mm margin (IMRT cut ). Plans with optimized coplanar and non-coplanar beam arrangements were generated. Differences in PTV coverage and sparing of organs at risk (OARs) were quantified. The impact of beam number on plan quality was evaluated. Results: Especially for patients with bilateral hip prostheses, IMRT cut significantly improved rectum and bladder sparing compared to IMRT remove . For 9-beam coplanar plans, rectum V 60Gy reduced by 17.5% ± 15.0% (maximum 37.4%, p = 0.036) and rectum D mean by 9.4% ± 7.8% (maximum 19.8%, p = 0.036). PTV coverage was similar, except for one patient who had a V 95% of only 22.3% for IMRT remove , compared to 99.1% for IMRT cut . Improved PTV coverage was only possible with a higher dose in all OARs (see figure) . Further improvements in OAR sparing were achieved by using non-coplanar beam set-ups, reducing rectum V 60Gy by another 4.6% ± 4.9% (p = 0.012) for non-coplanar 9-beam IMRT cut plans. Large reductions in rectum dose delivery were also observed when increasing the number of optimized beam directions in the plans. For bilateral implants, rectum V 60Gy was 37.3% ± 12.1% for coplanar 7-beam IMRT cut plans which reduced on average by 13.5% (maximum 30.1%, p = 0.012) for 15 optimized beam directions. Conclusions: For prostate cancer patients with metal hip implants, iCycle was able to automatically generate high quality, patientspecific IMRT plans with optimized coplanar or non-coplanar beam arrangements. Excluding only beamlets that would deliver dose to the PTV after passing through a prosthesis significantly improved OAR sparing for patients with bilateral implants as opposed to the AAPM taskgroup 63 recommendation. Non-coplanar beam arrangements and, to a larger extent, increasing the number of optimized treatment beams further improved plan quality. Purpose/Objective: Stereotactic body radiotherapy (SBRT) for nonsmall-cell lung cancer (NSCLC) has led to promising local control and overall survival for fractionation schemes with increasingly high fractional doses. A point has however been reached where too few fractions may be used to allow efficient inter-fraction reoxygenation (IFR) of the hypoxic cells possibly residing in the tumours. It was the purpose of this study to investigate the impact of hypoxia and extreme hypofractionation on the tumour control probability (TCP) using realistic 3D-models of tumour oxygenation. Materials and Methods: 3D-models of tumour oxygenation have been based on previous calculations of tumour oxygenation at cellular level for various distributions of intervascular distances. The models took into account dynamic changes in the oxygenation of the tumours between fractions. Simulations were performed for currently used fractionation schemes for NSCLC and for theoretical dose prescriptions that may be used in SBRT. Clinically relevant dose distributions were used to ensure the fulfilment of prescription details for dose escalation, dose to the PTV periphery and maximum dose. Cellular response was assessed with the LQ model at voxel level and a Poisson TCP model at tumour level. Results: Calculated tumour control probabilities with IFR agree best with reported clinical local control for multi-fraction schemes (Table  1) . The largest disagreement between the clinical figures and the calculated values are seen for the single-fraction schemes which could be caused by other biophysical processes believed to take place at high doses, but not included in the model, such as vascular endothelial apoptosis.TCP curves for 1, 3 and 5 fractions with and without IFR (Figure 1 ) demonstrate the importance of allowing for IFR. Furthermore, they suggest that 3 or 5 fractions are enough to ensure IFR. Table 1 . Examples of calculated TCP with and without IFR for the dose schemes pertinent to current clinical practice in the SBRT treatment of NSCLC with clinical figures of survival and local control. Normal-and tumour tissue BED:s are also given. † Dose range 24-40 Gy, 69% was given 37.5Gy ‡ Based on 60 Gy totaldoses given in 3, 5 and 8 fractions: 3x20 Gy(33%), 5x12 Gy (50%), 8x7.5 Gy(17%) Conclusions: Single-fraction stereotactic treatments may require a considerable increase in dose per fraction, well above fractional doses used today, to counteract the radioresistance of hypoxic cells. Although attractive from an economical and practical viewpoint, extreme hypofractionation in SBRT should therefore be pursued with caution as the reduced possibility for IFR may result in impaired local control. 
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